Breaks Categories: News

FridaySep 27, 2024 10:34 am

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”

Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, will be spotlighted during the upcoming episode of “Health Uncensored with Dr. Drew.” The show will be broadcast on Fox Business Network at 5:30 p.m. EST on Sept. 29, 2024. Dr. Drew will talk with Telomir Pharmaceuticals special advisor Dr. Michael F. Roizen, MD, about the science of longevity and the importance that telomeres, or the protective end caps of chromosomes, have on the aging process. During the episode, Roizen will explain how TELO’s Telomir-1-a novel small molecule has…

Continue Reading

ThursdaySep 26, 2024 10:40 am

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) for all antiviral drug developments from TheraCour. According to the announcement, the MoU encompasses all antiviral drug developments and is a crucial step that provides NanoViricides with certain intellectual property rights for developing treatments against any viral infections. The announcement noted that the MoU enables…

Continue Reading

WednesdaySep 25, 2024 11:10 am

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing Guys and St. Thomas Hospital, a London-based hospital with a leading oncology clinic and cell therapy clinical team, as a new site in the ACHIEVE UK Trial. The site opened in September 2024, expediting the progression of the trial timelines and increasing the velocity of enrollment. The ACHIEVE UK clinical trial is an open-label, Phase 2 study evaluating the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. “The progression…

Continue Reading

TuesdaySep 24, 2024 2:55 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity Conference held on Oct. 30, 2024, in New York City. According to the announcement, TC Biopharm CEO Bryan Kobel will be presenting at the conference. During his presentation, Kobel will provide an overview of the company's clinical trials along with recent improvements to TC BioPharm's balance sheet. Hosted by ThinkEquity, a boutique investment bank, the ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world. To view the…

Continue Reading

TuesdaySep 24, 2024 12:29 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence (“AI”) scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader and pioneer in digital health data analytics and body-worn biosensor technologies, Myers is a globally respected authority on utilizing AI in biosensor tech. In his new position, Myers will drive innovation and strategic growth for HeartBeam as the company looks to fully leverage its AI…

Continue Reading

TuesdaySep 24, 2024 10:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/3khUt About Nutriband Inc.…

Continue Reading

MondaySep 23, 2024 11:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/P0zd8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

Continue Reading

FridaySep 20, 2024 12:45 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

Continue Reading

ThursdaySep 19, 2024 11:25 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R). “We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration…

Continue Reading

ThursdaySep 19, 2024 11:10 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a partnership with Lyric Health, a comprehensive virtual care provider. This partnership, which entails integrating HealthLynked with Lyric Health, enables the company to expand its telehealth services nationwide to all 50 states. As part of this expansion, the company has introduced its new Virtual Urgent Care service, which enables members to connect with a licensed physician within an average of 20 minutes. Additionally, HealthLynked intends to launch its Virtual Primary Care service, which will allow users to set future appointments with primary care physicians, establishing ongoing relationships with virtual doctors.…

Continue Reading